Latest news with #MWA
New Straits Times
a day ago
- Entertainment
- New Straits Times
#SHOWBIZ: Malaysian stars align: Joe Flizzow, Dolla to open for Jay Park in KL
KUALA LUMPUR: Fans of South Korean superstar Jay Park are in for an unforgettable night as the global hip-hop and R&B icon announces the addition of two powerhouse Malaysian acts — Joe Flizzow and Dolla — as special guest performers at his '2025 World Tour [Serenades & Body Rolls] In Kuala Lumpur'. The highly anticipated concert is set to take place on June 14 at Zepp Kuala Lumpur. Known for his electrifying live performances and boundary-pushing artistry, Jay is showing his appreciation for the Malaysian music scene by inviting two of the country's most prominent stars to share his stage. Joe Flizzow, one of Malaysia's most respected voices in hip-hop, will bring his commanding presence and lyrical firepower to the show. A long-standing force in Southeast Asia's rap movement, his appearance is expected to deliver a powerful moment of cultural synergy and cross-border collaboration. Also joining the lineup is Dolla, Malaysia's premier girl group, whose recent single 'MWA' has taken the charts by storm, currently sitting in the Top 10 in Malaysia. With their dynamic choreography and fierce vocals, Dolla is set to inject a burst of energy into the night's performance and further solidify their rising status in the Asian pop scene. In a statement today, Jay said: "Joe Flizzow's been my brother for a long time, and Dolla's been making big moves out here. I'm excited to share the stage with both of them and show love to all the fans in Malaysia." The Kuala Lumpur show is part of Jay's extensive world tour that spans major cities across Asia, Australia, and New Zealand. With a reputation for unforgettable live shows and a lineup that now includes local chart-toppers, this concert is shaping up to be one of the year's most anticipated events.
Yahoo
19-05-2025
- Business
- Yahoo
Baird Medical Engages Global Clinical Leaders at AAES 2025
NEW YORK, May 19, 2025 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) ("Baird Medical" or the "Company"), a global leader in minimally invasive Microwave Ablation (MWA) technology, is pleased to announce its participation in the 45th Annual Meeting of the American Association of Endocrine Surgeons (AAES), taking place from May 17-19, 2025, at the Baird Center in Milwaukee, Wisconsin. The AAES Annual Meeting, a premier academic and clinical forum, convenes leading endocrine surgeons, researchers, and innovators globally to explore advancements in endocrine surgery. For Baird Medical, this event is a key platform to showcase its latest MWA technological achievements and to foster direct engagement with healthcare professionals, thereby gaining deeper insights into the evolving needs of the medical community. At this year's meeting, Baird Medical presented its pioneering MWA system for thyroid nodule treatment, emphasizing its benefits as a minimally invasive alternative to conventional surgery. The technology garnered considerable interest from attending surgeons, who recognized its potential to enhance patient outcomes by minimizing procedural risks, preserving thyroid function, and expediting recovery. Through substantive dialogues with clinical experts, Baird Medical acquired critical feedback on practical aspects including patient selection, ultrasound guidance optimization, and diverse application scenarios. The insights and perspectives gathered at AAES 2025 are pivotal for shaping Baird Medical's future clinical collaboration initiatives. By maintaining a close alignment with the requirements of surgeons and their patients, the Company remains committed to advancing its mission of delivering safer, more effective treatment solutions for thyroid and other endocrine diseases. About Baird Medical Baird Medical is a forward-thinking medical device company specializing in minimally invasive diagnostics and treatment. It is dedicated to the research and development of surgical robotic systems and innovative minimally invasive surgical instruments. Our mission is to enhance patient outcomes through precision technology and advanced diagnostic solutions. The company will foster strategic collaborations with leading academic institutions. Our vision extends beyond surgical assistance, aiming to develop intelligent systems that proactively guide diagnostic decisions and preventive healthcare strategies. As an FDA 510(k)-certified medical device company, Baird Medical's solutions have been used in over 30 prestigious hospitals and clinics across the United States, including Johns Hopkins Hospital, Tulane Medical Center, Weill Cornell Medicine, and Columbia University Medical Center. Baird Medical is also the market leader in China in thyroid microwave ablation devices and consumables. Meanwhile, the company's minimally invasive treatment products are gradually expanding their commercial presence in over 20 countries worldwide. Forward-Looking Statements This press release includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or Baird Medical's future financial or operating performance. In some cases, you can identify forward-looking statements by terminology such as "may", "could", "should", "expect", "intend", "might", "will", "estimate", "anticipate", "believe", "budget", "forecast", "intend", "plan", "potential", "predict", "potential" or "continue", or the negatives of these terms or variations of them or similar terminology. Forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Baird Medical and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Baird Medical does not undertake any duty to update these forward-looking statements. Actual results may vary materially from those expressed or implied by forward-looking statements based on a number of factors, including, without limitation: (1) the risk that Baird Medical may not be successful in expanding its business in China or the United States; (2) changes in general economic conditions; (3) regulatory conditions and developments; (4) changes in applicable laws or regulations; (5) the nature, cost and outcome of pending and future litigation and other legal proceedings instituted against Baird Medical or others; and (5) other risks and uncertainties from time to time described in the Registration Statement relating to the Business Combination and the transition report, including those listed under the sections titled "Risk Factors" therein, and in ExcelFin's other filings with the SEC. The foregoing list of factors is not exclusive. Additional information concerning certain of these and other risk factors is contained in ExcelFin's most recent filings with the SEC and in the Registration Statement described above filed by Baird Medical in connection with its business combination with ExcelFin. All subsequent written and oral forward-looking statements concerning Baird Medical, the business combination described herein or other matters attributable to Baird Medical or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements above. Readers are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Baird Medical expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in their expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based. Contact:Eric Huang, PR LiaisonBaird Medical Investment Holdings +1 (888) 508-6228Email: ir@ View original content to download multimedia: SOURCE BDMD Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
19-05-2025
- Business
- Yahoo
Baird Medical Engages Global Clinical Leaders at AAES 2025
NEW YORK, May 19, 2025 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) ("Baird Medical" or the "Company"), a global leader in minimally invasive Microwave Ablation (MWA) technology, is pleased to announce its participation in the 45th Annual Meeting of the American Association of Endocrine Surgeons (AAES), taking place from May 17-19, 2025, at the Baird Center in Milwaukee, Wisconsin. The AAES Annual Meeting, a premier academic and clinical forum, convenes leading endocrine surgeons, researchers, and innovators globally to explore advancements in endocrine surgery. For Baird Medical, this event is a key platform to showcase its latest MWA technological achievements and to foster direct engagement with healthcare professionals, thereby gaining deeper insights into the evolving needs of the medical community. At this year's meeting, Baird Medical presented its pioneering MWA system for thyroid nodule treatment, emphasizing its benefits as a minimally invasive alternative to conventional surgery. The technology garnered considerable interest from attending surgeons, who recognized its potential to enhance patient outcomes by minimizing procedural risks, preserving thyroid function, and expediting recovery. Through substantive dialogues with clinical experts, Baird Medical acquired critical feedback on practical aspects including patient selection, ultrasound guidance optimization, and diverse application scenarios. The insights and perspectives gathered at AAES 2025 are pivotal for shaping Baird Medical's future clinical collaboration initiatives. By maintaining a close alignment with the requirements of surgeons and their patients, the Company remains committed to advancing its mission of delivering safer, more effective treatment solutions for thyroid and other endocrine diseases. About Baird Medical Baird Medical is a forward-thinking medical device company specializing in minimally invasive diagnostics and treatment. It is dedicated to the research and development of surgical robotic systems and innovative minimally invasive surgical instruments. Our mission is to enhance patient outcomes through precision technology and advanced diagnostic solutions. The company will foster strategic collaborations with leading academic institutions. Our vision extends beyond surgical assistance, aiming to develop intelligent systems that proactively guide diagnostic decisions and preventive healthcare strategies. As an FDA 510(k)-certified medical device company, Baird Medical's solutions have been used in over 30 prestigious hospitals and clinics across the United States, including Johns Hopkins Hospital, Tulane Medical Center, Weill Cornell Medicine, and Columbia University Medical Center. Baird Medical is also the market leader in China in thyroid microwave ablation devices and consumables. Meanwhile, the company's minimally invasive treatment products are gradually expanding their commercial presence in over 20 countries worldwide. Forward-Looking Statements This press release includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or Baird Medical's future financial or operating performance. In some cases, you can identify forward-looking statements by terminology such as "may", "could", "should", "expect", "intend", "might", "will", "estimate", "anticipate", "believe", "budget", "forecast", "intend", "plan", "potential", "predict", "potential" or "continue", or the negatives of these terms or variations of them or similar terminology. Forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Baird Medical and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Baird Medical does not undertake any duty to update these forward-looking statements. Actual results may vary materially from those expressed or implied by forward-looking statements based on a number of factors, including, without limitation: (1) the risk that Baird Medical may not be successful in expanding its business in China or the United States; (2) changes in general economic conditions; (3) regulatory conditions and developments; (4) changes in applicable laws or regulations; (5) the nature, cost and outcome of pending and future litigation and other legal proceedings instituted against Baird Medical or others; and (5) other risks and uncertainties from time to time described in the Registration Statement relating to the Business Combination and the transition report, including those listed under the sections titled "Risk Factors" therein, and in ExcelFin's other filings with the SEC. The foregoing list of factors is not exclusive. Additional information concerning certain of these and other risk factors is contained in ExcelFin's most recent filings with the SEC and in the Registration Statement described above filed by Baird Medical in connection with its business combination with ExcelFin. All subsequent written and oral forward-looking statements concerning Baird Medical, the business combination described herein or other matters attributable to Baird Medical or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements above. Readers are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Baird Medical expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in their expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based. Contact:Eric Huang, PR LiaisonBaird Medical Investment Holdings +1 (888) 508-6228Email: ir@ View original content to download multimedia: SOURCE BDMD
Malay Mail
11-05-2025
- Entertainment
- Malay Mail
Malaysian girl group Dolla returns after a year with fresh, experimental sound in ‘MWA!' (VIDEO)
KUALA LUMPUR, May 11 — After not releasing any new song for a year, popular Malaysian girl group Dolla returns with their latest single, 'MWA!'. 'MWA!', created by Chelsea Warner, Gaston, Roland Lim Shi Jie, and the three members of Dolla — Tabby, Sabronzo and Angel — features a fresh and experimental sound that is expected to capture the attention of fans. Angel said they were very excited to collaborate once again with the creative team as it offered them a chance to explore new musical ideas that were more challenging and fun. 'After a year without releasing a single due to being busy with concerts and several other projects, this year we successfully released 'MWA!' for our beloved fans. This song feels like a rebranding of our identity. 'The recording session also went very smoothly. We experimented a lot with different sounds and structures, and the detailed involvement of every Dolla member this time made the creative process even more meaningful,' she said at a press conference after the launch of their new single in Bukit Bintang here. She also said the official music video for 'MWA!', with a duration of two minutes and 20 seconds and directed by Jasmine Wong, is different from their previous videos, taking viewers on a thrilling narrative of action and illusion from Dolla. Elaborating on the music video, Angel said each Dolla member portrays a unique character, with Sabronzo appearing as a card player and Tabby as the mastermind, while she herself takes on the role of an agile and bold fighter. 'This time, the concept is wilder and unhinged, very different from anything we've done before,' she said. Meanwhile, Tabby said 'MWA!' marks the beginning of many new works that Dolla will be presenting throughout the year. 'We consider this year the 'year of Dolla songs' because many more tracks will be released. We can't wait to bring them to the stage and hope they will attract more listeners because the songs are very fresh and different,' she said. — Bernama
Yahoo
10-05-2025
- Business
- Yahoo
Mueller Water price target lowered to $30 from $33 at Seaport Research
Seaport Research lowered the firm's price target on Mueller Water (MWA) to $30 from $33 and keeps a Buy rating on the shares. Tariffs increased cost of goods sold more than expected due to the China factory and sourcing, the analyst tells investors. Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter. Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders' Hot Stocks on TipRanks >> Read More on MWA: Disclaimer & DisclosureReport an Issue Mueller Water Products Highlights Q2FY25 Financial Performance Mueller Water Products Reports Strong Q2 2025 Results Mueller Water Products Reports Record Earnings Amid Challenges Mueller Water reports Q2 EPS 34c, consensus 31c Mueller Water raises FY25 revenue view to $1.39B-$1.40B from $1.37B-$1.39B Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
